TY - CHAP M1 - Book, Section TI - HYPERLIPIDEMIA A1 - Rosenson, Robert S. A1 - Grundy, Scott M. A2 - Fuster, Valentin A2 - Harrington, Robert A. A2 - Narula, Jagat A2 - Eapen, Zubin J. PY - 2017 T2 - Hurst's The Heart, 14e AB - SummaryThis chapter discusses the causes and effects of hyperlipidemia, as well as treatment strategies for the condition (see accompanying Hurst’s Central Illustration). The two main categories of hyperlipidemia are hypercholesterolemia and hypertriglyceridemia; combined hyperlipidemia indicates an increase in concentration of both cholesterol and triglycerides. An elevated plasma low-density lipoprotein (LDL) level is considered a major risk factor for atherosclerotic cardiovascular disease (ASCVD), and LDL-lowering therapies reduce atherosclerotic plaque progression and the likelihood of plaque rupture and acute ASCVD events. By contrast, high levels of high density lipoprotein (HDL)-cholesterol are associated with reduced risk of ASCVD; however, to date, no convincing randomized controlled trial data have demonstrated that raising HDL-cholesterol levels prevents the condition. Growing evidence indicates that very-low-density lipoprotein (VLDL), and possibly cyclomicron remnants, are also atherogenic. Several genetic defects have been associated with hypercholesterolemia and, in most cases, result in high levels of LDL-cholesterol. Similarly, various genetic abnormalities that affect VLDL, VLDL remnants, and/or chylomicrons have been associated with hypertriglyceridemia. Familial combined hyperlipidemia is likely a polygenic disorder. Secondary causes of hyperlipidemia include diabetes mellitus, nephrotic syndrome, chronic kidney disease, hypothyroidism, human immunodeficiency virus, and various medications. Lifestyle factors, including poor diet, obesity, low physical activity levels, and cigarette smoking, are also risk factors for hyperlipidemia and ASCVD. Therapies shown to lower lipid levels include statins, bile acid resins, ezetimibe, monoclonal antibody inhibitors of PCSK9, mipomersen, lomitapide, fibrates, niacin, and LDL apheresis. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesscardiology.mhmedical.com/content.aspx?aid=1191187093 ER -